Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus(®) Insulin Glargine

INTRODUCTION: We compared insulin antibody response (IAR) profiles in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) who received LY2963016 insulin glargine (LY IGlar) or Lantus(®) insulin glargine (IGlar) and evaluated the potential relationship between higher IARs and clinical and sa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Ther
Autores principales: Ilag, Liza L., Costigan, Timothy M., Deeg, Mark A., Pollom, Robyn K., Chang, Curtis L., Konrad, Robert J., Prince, Melvin J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5446380/
https://ncbi.nlm.nih.gov/pubmed/28361463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0253-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares